Axovant Sciences (AXON) Sell-Off Creates Buying Opportunity - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BMO Capital Reiterates Outperform on Pfizer (PFE) Following 4Q
February 3, 2016 8:21 AM ESTBMO Capital maintained an Outperform rating on Pfizer (NYSE: PFE), and cut the price target to $39.00 (from $41.00), following the company's 4Q earnings report. Good operational revenue growth drove a 3% top-line beat. The company's better-than-expected gross margin was offset by higher opex, but the lower tax rate helped drive the bottom-line penny beat. 2016 forecasts are below consensus, but BMO believes that the Street estimates will likely come down soon.
Analyst... More
Axovant Sciences (AXON) Defended at Baird on Pfizer Program Discontinuation-Related Selloff
February 2, 2016 1:00 PM ESTBaird analyst Brian Skorney said while the Pfizer discontinuation of the clinical program for PF-05212377 doesn't have a good read through for Axovant Sciences' (NYSE: AXON) RVT-101, they said the selloff creates buying opportunity.
"We see a number of reasons to think this is an oversimplification and see the disconnect as a buying opportunity," Skorney said.
"... would basically assert that this study has no predictive significance... More
